Metcort Adverse Reactions

Gastrointestinal Effects: Dyspepsia, diarrhea, esophagitis, peptic ulcer with possible perforation and hemorrhage, abdominal distention, abdominal pain, esophageal ulceration, esophageal candidiasis, pancreatitis, perforation of bowel, gastric hemorrhage, nausea.
Musculoskeletal Effects: Arthralgia, muscle atrophy, muscular weakness, myalgia, steroid myopathy, neuropathic arthropathy, avascular osteonecrosis, osteoporosis, pathological fracture, long bone and spinal compression fractures and tendon rupture (particularly of the Achilles tendon).
Skin and Subcutaneous Tissue Disorders: Impaired wound healing, petechiae, ecchymosis, thin fragile skin, erythema, skin atrophy, striae, hyperhidrosis, hirsutism, telangiectasia, acne, urticaria, rash and pruritus. Reports of Kaposi's sarcoma occurrence in patients receiving corticosteroid therapy; discontinuation of corticosteroids may result in clinical remission.
Endocrine-Metabolic Effects: Suppression of HPA axis; growth suppression in infants, children and adolescents; development of cushingoid state, increased appetite which may result in weight gain, impaired glucose tolerance, increased requirements for insulin or oral hypoglycemic agents in diabetes, increased appetite, manifestations of latent diabetes mellitus, pituitary unresponsiveness, negative nitrogen and calcium balance.
Psychiatric Effects: Abnormal behavior, affective disorder (including affect lability, depressed and euphoric mood, psychological dependence, suicidal ideation), behavioral disturbances (including anxiety, confusional state, insomnia, irritability), mental disorder, mood swings, personality change, psychotic behavior and disorders (including mania, delusion, hallucination and aggravation of schizophrenia).
Nervous System Effects: Amnesia, cognitive disorder, convulsions, dizziness, headache, increased intracranial pressure with papilledema (benign intracranial hypertension).
Ophthalmic Effects: Glaucoma, increased intraocular pressure, posterior subcapsular cataracts, exophthalmos, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal disease.
Cardiovascular Effects: Myocardial rupture following recent myocardial infarction, hypertension, hypotension, circulatory collapse.
Immune System Effects: Increased susceptibility to and severity of infections with suppression of clinical symptoms and signs, latent infections becoming active, including reactivation of tuberculosis and opportunistic infections, allergic reactions including anaphylactoid reactions, anaphylaxis and angioedema; may suppress reactions to skin tests.
Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients, hypokalemic alkalosis, metabolic acidosis, fluid retention, potassium loss, sodium retention and increased calcium excretion.
Investigations: Elevation of serum liver enzyme levels (alanine transaminase, aspartate transaminase and alkaline phosphatase), hypokalemia, increased calcium excretion/urine calcium.
Reproductive System and Breast Disorders: Menstrual irregularities and amenorrhea.
Ear and Labyrinth Disorders: Vertigo, impaired hearing.
Others: Hiccups, leukocytosis, malaise, withdrawal symptoms and moon face.